170 related articles for article (PubMed ID: 33902692)
21. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma.
Steffanoni S; Batchelor TT
Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302
[TBL] [Abstract][Full Text] [Related]
22. Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib.
Cheng Q; Wang J; Lv C; Xu J
Onco Targets Ther; 2021; 14():3367-3372. PubMed ID: 34079282
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.
Nepal G; Khurana M; Bucheli DH; Bhandari S; Joshi U; Bhagat R; Rehrig JH; Pudasainee P; Shing YK; Ortiz JF; Ojha R; Gajurel BP; Quinonez J; Ruxmohan S; Albert T; Licata S; Stien J
Neurol Int; 2022 Jan; 14(1):99-108. PubMed ID: 35076567
[TBL] [Abstract][Full Text] [Related]
24. Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.
Yang C; Cui Y; Ren X; Li M; Yu K; Shen S; Jiang H; Li M; Zhang X; Zhao X; Zhu Q; Lin S
Front Oncol; 2022; 12():901797. PubMed ID: 35785180
[TBL] [Abstract][Full Text] [Related]
25. Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.
Bhatti M; Ayton S; Michail O; Gollop ND; Ryding A; Rushworth S; Bowles K; Geisler T; Flather M
Thromb Res; 2019 Jul; 179():64-68. PubMed ID: 31082751
[TBL] [Abstract][Full Text] [Related]
26. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
27. [An elderly patient with lymphoplasmacytic lymphoma successfully treated with low-dose tirabrutinib].
Yasumi M; Shiraishi K; Kamijo K; Kamae T; Karasuno T
Rinsho Ketsueki; 2023; 64(4):245-249. PubMed ID: 37121766
[TBL] [Abstract][Full Text] [Related]
28. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
29. Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.
Shen J; Liu J
Front Oncol; 2022; 12():1034668. PubMed ID: 36465385
[TBL] [Abstract][Full Text] [Related]
30. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Walter HS; Rule SA; Dyer MJ; Karlin L; Jones C; Cazin B; Quittet P; Shah N; Hutchinson CV; Honda H; Duffy K; Birkett J; Jamieson V; Courtenay-Luck N; Yoshizawa T; Sharpe J; Ohno T; Abe S; Nishimura A; Cartron G; Morschhauser F; Fegan C; Salles G
Blood; 2016 Jan; 127(4):411-9. PubMed ID: 26542378
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).
Rule SA; Cartron G; Fegan C; Morschhauser F; Han L; Mitra S; Salles G; Dyer MJS
Leukemia; 2020 May; 34(5):1458-1461. PubMed ID: 31827243
[No Abstract] [Full Text] [Related]
32. Updates of primary central nervous system lymphoma.
Wu J; Zhou D; Zhu X; Zhang Y; Xiao Y
Ther Adv Hematol; 2024; 15():20406207241259010. PubMed ID: 38883164
[TBL] [Abstract][Full Text] [Related]
33. Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia.
Nakagawa N; Yamano R; Kajikawa S; Kondo Y; Okumura H
Leuk Res Rep; 2022; 17():100331. PubMed ID: 35669930
[TBL] [Abstract][Full Text] [Related]
34. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
[TBL] [Abstract][Full Text] [Related]
35. Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.
Muqbil I; Chaker M; Aboukameel A; Mohammad RM; Azmi AS; Ramchandren R
Heliyon; 2019 Aug; 5(8):e02290. PubMed ID: 31508518
[TBL] [Abstract][Full Text] [Related]
36. Refractory immune thrombocytopenic purpura associated with IgM monoclonal gammopathy of undetermined significance: Successful treatment with tirabrutinib plus conventional therapies.
Naka R; Kaneko H; Nagata O; Tada K; Tashima M; Mizutani C; Imada K
EJHaem; 2022 May; 3(2):513-516. PubMed ID: 35846034
[TBL] [Abstract][Full Text] [Related]
37. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Owen C; Berinstein NL; Christofides A; Sehn LH
Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
[TBL] [Abstract][Full Text] [Related]
38. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
Yasuhiro T; Sawada W; Klein C; Kozaki R; Hotta S; Yoshizawa T
Leuk Lymphoma; 2017 Mar; 58(3):699-707. PubMed ID: 27684575
[TBL] [Abstract][Full Text] [Related]
40. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Milpied N; Fung H; Topp MS; Houot R; Beitinjaneh A; Peng W; Zheng L; Rossi JM; Jain RK; Rao AV; Reagan PM
N Engl J Med; 2020 Apr; 382(14):1331-1342. PubMed ID: 32242358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]